Experimental drug with a RAS inhibitor for advanced pancreatic cancer
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests an experimental drug (SNV1521) combined with a RAS inhibitor for people with advanced pancreatic cancer. The goal is to see if this combination is safe and can help shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years old or older.
- Your pancreatic cancer must be at an advanced stage, meaning it cannot be removed with surgery or has spread to other parts of the body.
- A biopsy (tissue or cell sample) must have confirmed your cancer.
- You need at least one tumor that can be seen and measured on a scan.
- You must be healthy enough overall to receive the study treatment, as determined by the study doctor.
- You must be able to swallow oral medications (pills).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new targeted therapy (daraxonrasib) combined with standard chemotherapy as the first treatment for people whose pancreatic cancer has spread. The goal is to see if this combination can help shrink or control the cancer better than chemotherapy alone.
This study tests a new drug that targets a common genetic change (RAS) in pancreatic cancer, combined with other treatments. It aims to see if this combination is safe and effective for people whose cancer has advanced despite prior therapy.
This trial tests a new medicine (DN022150) combined with standard chemotherapy as a first treatment for advanced pancreatic cancer that has a specific genetic change called KRAS G12D. The combination may help shrink or slow the cancer better than chemotherapy alone.
This trial tests whether adding a new drug called zoldonrasib to standard chemotherapy works better than chemotherapy alone for pancreatic cancer that has spread and has a specific KRAS G12D mutation. The goal is to see if this combination helps patients live longer and control their cancer better.
This trial tests a new drug combined with other treatments for advanced pancreatic cancer. It aims to see if the combination can help people whose cancer has a specific genetic change called RAS mutation.
This trial tests two new targeted pills (zoldonrasib and daraxonrasib) compared to the standard chemotherapy (gemcitabine and nab-paclitaxel) as the first treatment for metastatic pancreatic cancer with a specific KRAS G12D mutation. The new pills may specifically attack cancer cells with this mutation.
Hear when a new Pancreatic cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.